Elevance Health: The Multi-Year Re-Rating Opportunity

Elevance is being framed as a trough-year story, with 2026 guided to at least $25.50 in EPS versus a normalized 2025 baseline of about $26.54 after stripping out $3.75 of one-time tax benefits. The upside thesis centers on Carelon margin expansion from 4.8% to 6.5%, which would add roughly $4.33 in EPS, while broader consolidated margin recovery could contribute another ~$7.11 per share. At roughly 13x forward earnings, the stock screens as discounted versus a 5-year average multiple near 17.7x, implying meaningful rerating potential if execution improves.

Analysis

ELV is a classic “bad year, better business” setup: the market is anchoring on a visible 2026 earnings trough while underpricing the option value in Carelon’s margin normalization. The second-order effect is that as management sheds lower-quality Medicare Advantage and absorbs Medicaid pressure, the remaining book should become less volatile and more financeable, which can support a higher multiple before the EPS bridge is fully realized.

The key misread is that the upside does not require heroic top-line growth; it only requires execution on a very large installed revenue base. Even modest operating leverage in Carelon and a modest enterprise-wide margin lift can compound quickly into several dollars of EPS, which matters far more than the near-term headline EPS dip. That creates an asymmetric setup: the market is paying for a trough narrative, but the business is transitioning toward a steadier cash-generating platform.

The main risk is timing. Medicaid utilization and reimbursement pressure can persist for multiple quarters, and if Carelon margin expansion stalls, the stock can remain range-bound despite improved fundamental quality. The contrarian point is that consensus may be too focused on the visible reset and not enough on the fact that the company is intentionally sacrificing short-term optics to improve the earn-back profile over 12-24 months.

Relative to peers, ELV looks better as a long-only recovery compounder than as a pure defensive healthcare holding. UNH and CI are the cleaner expressions of managed-care quality, but ELV offers the highest torque if the integration story works, making it the more interesting risk/reward for investors willing to look through the next 2-4 quarters.

Key Decisions for Investors

• Go long ELV on weakness over the next 1-3 months; use 12-18 month horizon and size for a 20-30% upside case if the market starts capitalizing Carelon’s margin bridge.
• Pair trade: long ELV / short CI or UNH as a relative-value expression on execution upside; ELV has more operating leverage if integration gains come through, while the short leg reduces sector beta.
• Sell downside premium in ELV via put spreads or cash-secured puts into earnings/guidance windows; the trough narrative should cap downside unless 2026 guidance is cut again.
• If ELV rallies sharply before evidence of margin improvement, trim into strength rather than chase; the multiple rerating is likely to be gradual and depends on quarterly proof points.
• For a higher-risk expression, buy 2026-2027 call spreads in ELV to monetize the gap between near-term trough earnings and longer-dated normalization.